Taiho Ventures, LLC will invest in global biotech ventures that align with our corporate growth strategy.
Employees: 1-10
Investment Type: Venture Capital
Investment Stage: Seed; Series B
Portfolio 21
| Date | Name | Website | Total Raised | Location |
| 27.07.2023 | hC Bioscie... | hcbioscience.com | - | United Sta... |
| 27.07.2023 | cellvie In... | cellvie.bio | $5.5M | Switzerlan... |
| 10.11.2022 | Normunity | normunity.com | $140M | United Sta... |
| 09.08.2022 | Transition... | transitionbio.com | $50M | United Sta... |
| 26.11.2021 | » English | liberothera.com | - | - |
| 26.11.2021 | Parthenon | parthenontx.com | $65M | United Sta... |
| 29.04.2021 | Anavo Ther... | anavotx.com | $85.32M | Netherland... |
| 04.03.2021 | Theolytics | theolytics.com | $33.12M | United Kin... |
| 04.03.2021 | Orna Thera... | ornatx.com | $321M | United Sta... |
| 07.11.2020 | Dren Bio, ... | drenbio.com | $125M | United Sta... |
Show more
Mentions in press and media 5
| Date | Title | Description |
| 09.09.2025 | cellvie secures $5 million to accelerate clinical translation | The Harvard Medical School spin-out and pioneer in mitochondria-based therapeutics, cellvie, developed off-the-shelf human cell line derived mitochondria as a scalable biologic. The Zurich-based biotech company is advancing two main progra... |
| 06.02.2023 | $5.5 million for cellvie | |
| 20.06.2019 | Axial Biotherapeutics Announces $10M Investment from Taiho Ventures | WALTHAM, Mass.--(BUSINESS WIRE)--Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted therapeutics for neurodegenerative diseases and neurodevelopmental disorders, today announced a direct inve... |
| 16.10.2018 | Taiho Ventures Expands Investment Pool to US$300M | Taiho Ventures, the strategic corporate venture capital arm of Taiho Pharmaceutical, Co., Ltd., increased its investment pool by US$250m from the initial US$50m to US$300m. A subsidiary of Otsuka Holdings Co., Ltd., Taiho Pharmaceutical is ... |
| - | Anavo Therapeutics Launches with EUR 20 Million Seed Financing to Create Industry-Leading Pipeline of Allosteric Phosphatase Modulators | Seed round was led by M Ventures and INKEF Capital, and co-led by Taiho Ventures and Bioqube Ventures |